Advances in the treatment of heart failure and the management strategies in general practice
10.3760/cma.j.cn114798-20250324-00252
- VernacularTitle:心力衰竭治疗进展与全科管理策略
- Author:
Ke CHAI
1
;
Hua WANG
1
Author Information
1. 北京医院心血管内科 国家老年医学中心 中国医学科学院老年医学研究院，北京 100730
- Publication Type:Journal Article
- Keywords:
Heart failure;
Therapeutic;
Universal prevention;
Management;
General practitioner
- From:
Chinese Journal of General Practitioners
2025;24(7):769-777
- CountryChina
- Language:Chinese
-
Abstract:
The prevention and control of heart failure (HF) remains challenging in China. Encouragingly, significant therapeutic advancements have emerged in recent years. In pharmacotherapy, angiotensin receptor neprilysin inhibitors (ARNIs) are supported by growing evidence, while finerenone improves outcomes in patients with heart failure with preserved ejection fraction (HFpEF). Sodium-glucose co-transporter 2 (SGLT2) inhibitors are applicable across all HF subtypes, and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) benefit obese patients with HFpEF. Vericiguat, a soluble guanylate cyclase stimulator, improves prognosis in patients with heart failure with reduced ejection fraction (HFrEF). The traditional Chinese medicine Qili Qiangxin Capsule has been shown to reduce cardiovascular death or HF exacerbation in HFrEF patients. Diuretics remain foundational for congestion relief, with improved strategies addressing diuretic resistance. Non-pharmacological interventions, such as cardiac implantable electronic devices (CIEDs) and transcatheter valve therapies, expand options for diverse HF stages. Adherence to guideline-directed management is critical to translating these advancements into patient benefits. General practitioners play a pivotal role in early screening of high-risk populations, long-term follow-up of chronic HF patients, and coordinated management of comorbidities, ultimately reducing disease burden and improving outcomes of HF patients.
